Idexx Labs (IDXX) Tops Q3 EPS by 1c; Raises FY11 Outlook; Guides FY12
Idexx Laboratories, Inc. (NASDAQ: IDXX) reported Q3 EPS of $0.66, $0.01 better than the analyst estimate of $0.65. Revenue for the quarter came in at $301 million versus the consensus estimate of $294.88 million.
Idexx Laboratories, Inc. sees FY2011 EPS of $2.71-$2.74, versus prior guidance of $2.68-$2.73 and the consensus of $2.72. Idexx Laboratories, Inc. sees FY2011 revenue of $1.215 billion, versus prior guidance of $1.205-$1.215 billion and the consensus of $1.21 billion.
Idexx Laboratories, Inc. sees FY2012 EPS of $3.00-$3.10, versus the consensus of $3.06. Idexx Laboratories, Inc. sees FY2012 revenue of $1.295-$1.315 billion, versus the consensus of $1.30 billion.
Idexx Laboratories, Inc. sees FY2011 EPS of $2.71-$2.74, versus prior guidance of $2.68-$2.73 and the consensus of $2.72. Idexx Laboratories, Inc. sees FY2011 revenue of $1.215 billion, versus prior guidance of $1.205-$1.215 billion and the consensus of $1.21 billion.
Idexx Laboratories, Inc. sees FY2012 EPS of $3.00-$3.10, versus the consensus of $3.06. Idexx Laboratories, Inc. sees FY2012 revenue of $1.295-$1.315 billion, versus the consensus of $1.30 billion.